Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
By Mauro Orru
Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop cancer treatments.
The Swiss pharmaceutical company said Thursday that it would pay $1 billion up front for Watertown, Mass.-based Mariana Oncology, with an additional $750 million in payments upon completion of certain milestones.
Mariana Oncology focuses on novel radioligand therapies, or RLTs, to treat cancers. RLTs bind to specific receptors on the surface of certain types of tumors. Once bound, emissions from therapeutic radioisotopes cause DNA damage that can inhibit cell growth and replication.
Novartis currently has two approved RLTs for patients with metastatic castration-resistant prostate cancer and certain types of gastroenteropancreatic neuroendocrine tumors.
The deal is subject to customary closing conditions.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 02, 2024 07:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing